{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:16:29Z","timestamp":1780960589340,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LYY21H310005"],"award-info":[{"award-number":["LYY21H310005"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020777","name":"Zhejiang Pharmaceutical Association","doi-asserted-by":"publisher","award":["2022ZYYL01"],"award-info":[{"award-number":["2022ZYYL01"]}],"id":[{"id":"10.13039\/501100020777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.intimp.2023.110344","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T18:36:08Z","timestamp":1685126168000},"page":"110344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study"],"prefix":"10.1016","volume":"120","author":[{"given":"Ziqi","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9338-9398","authenticated-orcid":false,"given":"Yanfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2023.110344_b0005","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jcmm.16151","article-title":"Therapy for Advanced Cholangiocarcinoma: Current Knowledge and Future Potential","volume":"25","author":"Wang","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.intimp.2023.110344_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.11.006","article-title":"Cholangiocarcinoma: What Are the Options in All Comers and How Has the Advent of Molecular Profiling Opened the Way to Personalised Medicine ?","volume":"179","author":"Roth","year":"2023","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2023.110344_b0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The Next Horizon in Mechanisms and Management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev.Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.intimp.2023.110344_b0020","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A Phase 2 and Biomarker Study of Cabozantinib in Patients with Advanced Cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2023.110344_b0025","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2012.41.5984","article-title":"Prognostic Nomogram for Intrahepatic Cholangiocarcinoma after Partial Hepatectomy","volume":"31","author":"Wang","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.intimp.2023.110344_b0030","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin Plus Gemcitabine Versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.intimp.2023.110344_b0035","first-page":"824","article-title":"Gemcitabine, Cisplatin, and Nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","volume":"5","author":"Shroff","year":"2019","journal-title":"J. Am. Med. Assoc.Oncol"},{"key":"10.1016\/j.intimp.2023.110344_b0040","article-title":"First-Line Chemotherapy in Advanced Biliary Tract Cancer Ten Years after the Abc-02 Trial: \u201cAnd yet It Moves!\u201d","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat. Res.Commun"},{"issue":"4","key":"10.1016\/j.intimp.2023.110344_b0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/13543784.2021.1897102","article-title":"Durvalumab: An Investigational Anti-Pd-L1 Antibody for the Treatment of Biliary Tract Cancer","volume":"30","author":"Rizzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.intimp.2023.110344_b0050","doi-asserted-by":"crossref","first-page":"e001042","DOI":"10.1136\/esmoopen-2020-001042","article-title":"The DNA Damage Repair (Ddr) Pathway in Biliary Tract Cancer (Btc): A New Pandora's Box?","volume":"5","author":"Ricci","year":"2020","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.intimp.2023.110344_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results from the Phase Ii Keynote-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.intimp.2023.110344_b0060","article-title":"Landscape of Microsatellite Instability across 39 Cancer Types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.intimp.2023.110344_b0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2022.09.031","article-title":"Comparative Assessment of Early Mortality Risk Upon Immune Checkpoint Inhibitors Alone or in Combination with Other Agents across Solid Malignancies: A Systematic Review and Meta-Analysis","volume":"177","author":"Viscardi","year":"2022","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2023.110344_b0070","first-page":"1","article-title":"Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJMEvid"},{"issue":"8","key":"10.1016\/j.intimp.2023.110344_b0075","first-page":"611","article-title":"Nivolumab Alone or in Combination with Cisplatin Plus Gemcitabine in Japanese Patients with Unresectable or Recurrent Biliary Tract Cancer: A Non-Randomised, Multicentre, Open-Label, Phase 1 Study","volume":"4","author":"Ueno","year":"2019","journal-title":"LancetGastroenterol Hepatol"},{"key":"10.1016\/j.intimp.2023.110344_b0080","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2147\/OTT.S195537","article-title":"Efficacy and Safety of Nivolumab for Metastatic Biliary Tract Cancer","volume":"12","author":"Gou","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.intimp.2023.110344_b0085","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/07853890.2022.2048416","article-title":"Real-World Outcomes of Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Programmed Cell Death Protein-1-Targeted Immunotherapy","volume":"54","author":"Deng","year":"2022","journal-title":"Ann. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.110344_b0090","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.21037\/jgo-20-562","article-title":"A Real-World Study of the Efficacy and Safety of Anti-Programmed Cell Death-1 Therapy Combined with Chemotherapy or Targeted Therapy in Patients with Advanced Biliary Tract Cancer","volume":"11","author":"Sun","year":"2020","journal-title":"J Gastrointest Oncol"},{"issue":"9","key":"10.1016\/j.intimp.2023.110344_b0095","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00262-019-02386-w","article-title":"Anti-Pd-1 Therapy Combined with Chemotherapy in Patients with Advanced Biliary Tract Cancer","volume":"68","author":"Sun","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.intimp.2023.110344_b0100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.hbpd.2022.08.015","article-title":"Current and Emerging Immunotherapeutic Approaches for Biliary Tract Cancers","volume":"21","author":"Yuan","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.intimp.2023.110344_b0105","doi-asserted-by":"crossref","first-page":"894407","DOI":"10.3389\/fphar.2022.894407","article-title":"Lenvatinib Combined with a Pd-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma","volume":"13","author":"Xie","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.intimp.2023.110344_b0110","doi-asserted-by":"crossref","unstructured":"R.K. Kelley, M. Ueno, C. Yoo, R.S. Finn, J. Furuse, Z. Ren, Pembrolizumab in Combination with Gemcitabine and Cisplatin Compared with Gemcitabine and Cisplatin Alone for Patients with Advanced Biliary Tract Cancer (Keynote-966): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial, The Lancet Online. Epub 2023\/4\/16. doi: https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","DOI":"10.1016\/S0140-6736(23)00727-4"},{"issue":"6","key":"10.1016\/j.intimp.2023.110344_b0115","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of Liver Function in Patients with Hepatocellular Carcinoma: A New Evidence-Based Approach-the Albi Grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.intimp.2023.110344_b0120","first-page":"522","article-title":"Gemcitabine and Cisplatin Plus Durvalumab with or without Tremelimumab in Chemotherapy-Naive Patients with Advanced Biliary Tract Cancer: An Open-Label, Single-Centre, Phase 2 Study","volume":"7","author":"Oh","year":"2022","journal-title":"LancetGastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110344_b0125","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2022.09.004","article-title":"Rational Development of Combination Therapies for Biliary Tract Cancers","volume":"78","author":"Harding","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110344_b0130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jmri.28214","article-title":"Apparent Diffusion Coefficient Mri Shows Association with Early Progression of Unresectable Intrahepatic Cholangiocarcinoma with Combined Targeted-Immunotherapy","volume":"57","author":"Sheng","year":"2023","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.intimp.2023.110344_b0135","doi-asserted-by":"crossref","first-page":"1071439","DOI":"10.3389\/fonc.2022.1071439","article-title":"Vascular Invasion and Lymph Node Metastasis Mediate the Effect of Ca242 on Prognosis in Hilar Cholangiocarcinoma Patients after Radical Resection","volume":"12","author":"Heng","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.intimp.2023.110344_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12122041","article-title":"Liver Tumor Markers, Halp Score, and Nlr: Simple, Cost-Effective, Easily Accessible Indexes for Predicting Prognosis in Icc Patients after Surgery","volume":"12","author":"Zhang","year":"2022","journal-title":"J Pers Med"},{"issue":"12","key":"10.1016\/j.intimp.2023.110344_b0145","doi-asserted-by":"crossref","first-page":"e12403","DOI":"10.1016\/j.heliyon.2022.e12403","article-title":"A Novel Prognostic Model to Predict Os and Dfs of Stage Ii\/Iii Gastric Adenocarcinoma Patients in China","volume":"8","author":"Li","year":"2022","journal-title":"Heliyon"},{"issue":"7","key":"10.1016\/j.intimp.2023.110344_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071862","article-title":"Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the Albi Grade","volume":"12","author":"Pinato","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2023.110344_b0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001945","article-title":"Ipilimumab and Nivolumab\/Pembrolizumab in Advanced Hepatocellular Carcinoma Refractory to Prior Immune Checkpoint Inhibitors","volume":"9","author":"Wong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.intimp.2023.110344_b0160","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.intimp.2023.110344_b0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Disease: A Systematic Review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.110344_b0170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/apt.16217","article-title":"Systematic Review with Meta-Analysis: Safety and Tolerability of Immune Checkpoint Inhibitors in Patients with Pre-Existing Inflammatory Bowel Diseases","volume":"53","author":"Meserve","year":"2021","journal-title":"Aliment Pharmacol Ther"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:56:21Z","timestamp":1761587781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923006677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":34,"alternative-id":["S1567576923006677"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110344","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110344"}}